Edwards’ TAVR sales faced ongoing hospital constraints in Q3

Oct 25, 2024 · Edwards’ TAVR sales faced ongoing hospital constraints in Q3 ... Q3 sales: $1.35 billion. 8.9% increase year over year TAVR sales: $1.02 billion. 6.5% increase year over year. …

CouponFollow Extension

9%
OFF

Edwards’ TAVR Sales Faced Ongoing Hospital Constraints In Q3

1 day from now

Oct 25, 2024 · Edwards’ TAVR sales faced ongoing hospital constraints in Q3 ... Q3 sales: $1.35 billion. 8.9% increase year over year TAVR sales: $1.02 billion. 6.5% increase year over year. …

medtechdive.com

$1.32
OFF

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS

1 day from now

Oct 27, 2022 · Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2022. Third Quarter Highlights and Outlook Q3 sales of $1.32 billion …

edwards.com

2%
OFF

Edwards Lifesciences Stock Skids On Weak Expectations For Its …

1 day from now

Oct 25, 2024 · Excluding that, Edwards' sales still narrowly missed the $1.37 billion forecast. Total TAVR sales climbed 7.2% in constant currency to $1.01 billion. The company says its …

investors.com

$907
OFF

EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS

1 day from now

Jul 28, 2022 · Transcatheter Aortic Valve Replacement (TAVR) In the second quarter, the company reported TAVR sales of $907 million, a year-over-year increase of 1 percent, or 5 …

edwards.com

$850
OFF

Edwards TAVR Volumes Tepid In October, Quashing Hopes Of Fast …

1 day from now

Oct 28, 2021 · Faced with continued headwinds, Edwards forecast fourth quarter TAVR sales of $850 million to $910 million, compared to the $944 million expected by analysts. ... Edwards’ …

medtechdive.com

FAQs about Edwards’ TAVR sales faced ongoing hospital constraints in Q3 Coupon?

How did Edwards' TAVR sales perform in the third quarter?

Outside the U.S., in the third quarter, Edwards' constant currency TAVR sales grew in the low-double digits on a year-over-year basis. Long-term, the company sees excellent opportunities for international growth as TAVR therapy adoption remains low. Globally, the company's local average selling prices and market positions were stable. ...

How did TAVR perform in the third quarter?

In the third quarter, the company reported TAVR sales of $862 million, a year-over-year increase of 1 percent, or 6 percent on a constant currency basis. Sales were impacted primarily by persistent U.S. hospital staffing shortages and COVID headwinds in Japan, which intensified the typical summer seasonality. ...

Does Edwards TAVR technology reduce paravalvular leak?

A study of Edwards’ latest TAVR technology, the SAPIEN 3 Ultra RESILIA valve, found lower rates of paravalvular leak (PVL) at 30 days, lower echo-derived gradients and larger effective orifice areas across all valve sizes when compared to the SAPIEN 3 and SAPIEN 3 Ultra valves. ...

Will TAVR reach $10 billion by 2028?

Globally, the company's local average selling prices and market positions were stable. The company continues to estimate that the global TAVR opportunity will reach $10 billion by 2028, implying a low double-digit compounded annual growth rate. Transcatheter Mitral and Tricuspid Therapies (TMTT) ...

Why did transcatheter Therapeutics increase 4% in the third quarter?

This increase was driven by an expansion of field-based personnel to support growth of the company's transcatheter therapies, including the launch and rollout of the PASCAL and EVOQUE systems. Research and development expenses increased 4% in the third quarter to $253 million, or 18.7% of sales. ...

Are Edwards TAVR platforms effective in reducing PVL?

The study found that all Edwards TAVR platforms demonstrated excellent PVL results. Notably, there was a statistically significant reduction in PVL for the 29 mm SAPIEN 3 Ultra RESILIA valve as compared to the 29 mm SAPIEN 3, with 88.3% of patients exhibiting no PVL and only 10.7% of patients exhibiting mild PVL. ...